Meeting News Coverage

Loteprednol gel effectively resolves pain, flare, cells after cataract surgery

PHOENIX – Study results showed that the recently approved loteprednol etabonate gel successfully treated ocular inflammation and pain in postcataract surgery patients, according to a poster presented here at Academy 2012.

Loteprednol etabonate was approved in 1998 in suspension form for treatment of steroid-responsive inflammatory conditions and postoperative inflammation after surgery, according to the poster. The recently approved gel formulation (loteprednol etabonate gel 0.5%) has improved loteprednol etabonate dose uniformity and is designed to increase surface retention, the researchers said...

The study by Comstock and colleagues looked at 813 patients with postoperative anterior chamber cells of at least grade 2 after cataract surgery. The patients were randomized to loteprednol etabonate gel or vehicle four times daily for 14 days.

“At all postoperative visits, significantly more loteprednol etabonate gel-treated patients than vehicle-treated patients had complete resolution of anterior chamber cells and flare and no pain,” according to the poster.

Disclosure: This study was sponsored by Bausch + Lomb.

PHOENIX – Study results showed that the recently approved loteprednol etabonate gel successfully treated ocular inflammation and pain in postcataract surgery patients, according to a poster presented here at Academy 2012.

Loteprednol etabonate was approved in 1998 in suspension form for treatment of steroid-responsive inflammatory conditions and postoperative inflammation after surgery, according to the poster. The recently approved gel formulation (loteprednol etabonate gel 0.5%) has improved loteprednol etabonate dose uniformity and is designed to increase surface retention, the researchers said...

The study by Comstock and colleagues looked at 813 patients with postoperative anterior chamber cells of at least grade 2 after cataract surgery. The patients were randomized to loteprednol etabonate gel or vehicle four times daily for 14 days.

“At all postoperative visits, significantly more loteprednol etabonate gel-treated patients than vehicle-treated patients had complete resolution of anterior chamber cells and flare and no pain,” according to the poster.

Disclosure: This study was sponsored by Bausch + Lomb.

    See more from Academy 2012